Daily Archives: May 28, 2022

2022-05-28: News Headlines

Allan Fisher (2022-05-28). Saturday 5/28: All Out for Palestine. indybay.org Ocean at Water Street, Santa Cruz…

Brenda Norrell (2022-05-28). Navajo Grandmother Honored with International Uranium Film Fest Award. indybay.org Dine' grandmother Elsie Begay, 83, of Monument Valley was honored with the Honorary Lifetime Achievement Award from the International Uranium Film Festival. Begay received her award in Dine' and English languages yesterday. Indigenous People around the world have been targeted with uranium mining, nuclear dumping, and atomic bomb testing. Radioactive tailings left behind by reckless corporations are strewn on the Navajo Nation and around the world. The award presentation and speakers video is available to view.

Chloe Wilson (2022-05-28). [Perspectives] Impossible times. thelancet.com During the COVID-19 pandemic health-care workers have often found themselves in the media spotlight. The pandemic has been framed as a war, and health-care workers have been labelled as soldiers on the front line. But using a wartime narrative to depict the pandemic is dangerous "None of you think you are soldiers, dodging spinning bullets shaped like pretty viral crowns", asserts Roopa Farooki in her book Everything is True: A Junior Doctor's Story of Life, Death and Grief in a Time of Pandemic.

Marc Ferrante, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean-Frederic Colombel, Silvio Danese, Marla Dubinsky, Brian G Feagan, Tadakazu Hisamatsu, Allen Lim, James O Lindsay, Edward V Loftus, Julián Panés, Laurent Peyrin-Biroulet, Zhihua Ran, David T Rubin, William J Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Geert D'Haens (2022-05-28). [Articles] Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. thelancet.com Subcutaneous risankizumab is a safe and efficacious treatment for maintenance of remission in patients with moderately to severely active Crohn's disease and offers a new therapeutic option for a broad range of patients by meeting endpoints that might change the future course of disease.

The Lancet (2022-05-28). [Editorial] A hunger for action. thelancet.com The basic nutritional needs of children are at grave risk. Worldwide, more than 13 ∑6 million children under 5 years have severe acute malnutrition, a serious wasting condition associated with poverty and prolonged insufficient access to food. Severe acute malnutrition weakens children's immunity, resulting in repeated rounds of diarrhoea and other infections, such as measles and malaria, and accounts for a fifth of deaths in this age group. In an alert released on May 17, UNICEF warned that over 10 million of these children do not have access to ready-to-use therapeutic food (RUTF), considered the most effec…

Richard Horton (2022-05-28). [Comment] Offline: The fairy tale of Paris. thelancet.com Are we fools? Do we really believe that the 2015 Paris Agreement will limit global warming to well below 2 ∞C, and preferably to 1 ∑5 ∞C, compared with pre-industrial levels? Commitments made by countries today would limit warming to about 2 ∑4 ∞C (with a range up to 3 ∑7 ∞C). We are way off track to meet the aspirations of Paris. For those who believe we should maintain our optimism—after all, hope encourages action, pessimism feeds nihilism—please consider reading Daniel Yergin's book about energy and climate, The New Map: Energy, Climate, and the Clash of Nations…

Geert D'Haens, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean-Frederic Colombel, Silvio Danese, Marla Dubinsky, Brian G Feagan, Tadakazu Hisamatsu, Allen Lim, James O Lindsay, Edward V Loftus, Julian Panés, Laurent Peyrin-Biroulet, Zhihua Ran, David T Rubin, William J Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Marc Ferrante (2022-05-28). [Articles] Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. thelancet.com Risankizumab was effective and well tolerated as induction therapy in patients with moderately to severely active Crohn's disease.

2022-05-28 22:08 | 18:08 EST | jz | 9 | 0 | 0 | 7 | 0